All conditions

Parkinson's Disease

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

26
Trials tracked
2
Recruiting now
24
Australian sites
50
Countries
Country

Showing 26 trials

🇦🇺 AU site

Trial: NCT06307431 — Merck Sharp & Dohme LLC

NCT06307431 · Merck Sharp & Dohme LLC
Active, Not Recruiting Phase 2 Est. completion 8 January 2028
🇦🇷 AR 🇦🇺 AU 🇨🇦 CA 🇨🇱 CL 🇫🇷 FR

**Who might be able to join this trial:** - You have been confirmed by a lab test (biopsy or cell sample) to have kidney cancer (renal cell carcinoma) of a specific type — either "clear cell" or "papillary." - Your kidney cancer is classed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06504394 — Merck Sharp & Dohme LLC

NCT06504394 · Merck Sharp & Dohme LLC
Active, Not Recruiting Phase 2 Est. completion 8 November 2028
🇦🇺 AU 🇨🇱 CL 🇩🇪 DE 🇲🇽 MX 🇳🇿 NZ

**Who might be able to join this trial:** - You have been diagnosed with classical Hodgkin lymphoma (a type of blood cancer) or primary mediastinal B-cell lymphoma (a type of lymphoma in the chest), confirmed by a tissue biopsy - Your canc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03711032 — Merck Sharp & Dohme LLC

NCT03711032 · Merck Sharp & Dohme LLC
Active, Not Recruiting Phase 3 Est. completion 31 July 2026
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with high-risk bladder cancer that has not grown into the muscle wall (specifically types called T1, high-grade Ta, and/or CIS), confirmed by a specialist review - You hav...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04626518 — Merck Sharp & Dohme LLC

NCT04626518 · Merck Sharp & Dohme LLC
Active, Not Recruiting Phase 2 Est. completion 17 July 2026
🇦🇺 AU 🇨🇦 CA 🇨🇱 CL 🇫🇷 FR 🇭🇺 HU

**Who might be able to join this trial:** - You have been diagnosed with a specific type of kidney cancer called clear cell renal cell carcinoma (ccRCC) that has spread to nearby tissues or other parts of the body, confirmed by a tissue sa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05152147 — Jazz Pharmaceuticals

NCT05152147 · Jazz Pharmaceuticals
Active, Not Recruiting Phase 3 Est. completion 31 July 2026
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a specific type of stomach or esophageal cancer (called HER2-positive adenocarcinoma) that cannot be removed by surgery, has come back, or has spread — confirmed by la...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04739423 — CuraSen Therapeutics, Inc.

NCT04739423 · CuraSen Therapeutics, Inc.
Completed Phase 2 Est. completion 4 July 2022
🇦🇺 AU 🇳🇿 NZ 🇬🇧 GB

**Who might be able to join this trial:** *For people with Parkinson's Disease (PD):* - You are between 40 and 80 years old at the time you agree to join the study. - You have been diagnosed with Parkinson's Disease and also have a sleep c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03517449 — Eisai Inc.

NCT03517449 · Eisai Inc.
Completed Phase 3 Est. completion 1 March 2022
🇦🇷 AR 🇦🇺 AU 🇧🇷 BR 🇨🇦 CA 🇨🇴 CO

**Who might be able to join this trial:** - You have been diagnosed with endometrial cancer (cancer of the lining of the uterus), confirmed by a tissue sample (biopsy) - Your cancer has spread, come back, or reached an advanced stage - You...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04003636 — Merck Sharp & Dohme LLC

NCT04003636 · Merck Sharp & Dohme LLC
Completed Phase 3 Est. completion 15 December 2022
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with advanced or inoperable bile duct cancer (either inside or outside the liver) or gallbladder cancer, confirmed by a tissue test. - Your cancer can be measured on scans,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01173731 — Novartis Pharmaceuticals

NCT01173731 · Novartis Pharmaceuticals
Completed Phase 2 Est. completion 1 October 2013
🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

Who might be able to join this trial: - You have Parkinson's disease and are being treated with a medication called L-Dopa - You experience involuntary movements (called dyskinesias) as a result of your Parkinson's treatment - You are an ou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02989610 — Abbott Medical Devices

NCT02989610 · Abbott Medical Devices
Completed Not Applicable Est. completion 7 August 2019
🇦🇺 AU 🇧🇪 BE 🇩🇪 DE 🇮🇹 IT 🇵🇱 PL

Who might be able to join this trial: - You are able to give your own consent to take part in the study - You have been diagnosed with Parkinson's disease and your doctor has recommended you receive, or you have already received, a specific...

🇦🇺 AU site

Trial: NCT00738062 — Chelsea Therapeutics

NCT00738062 · Chelsea Therapeutics
Completed Phase 3 Est. completion 1 December 2010
🇦🇺 AU 🇨🇦 CA 🇳🇿 NZ 🇺🇸 US

**Who might be able to join this trial:** - You took part in the earlier Droxidopa study called Protocol 302 - You are willing and able to give written consent to participate, and understand you can leave the study at any time without it af...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03361865 — Incyte Corporation

NCT03361865 · Incyte Corporation
Completed Phase 3 Est. completion 9 August 2018
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with advanced, inoperable, or spread (metastatic) bladder cancer or cancer of the renal pelvis, ureter, or urethra, confirmed by a lab test on a tissue or cell sample. - Yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03781167 — AbbVie

NCT03781167 · AbbVie
Completed Phase 3 Est. completion 17 August 2022
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇩🇰 DK 🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with Parkinson's Disease that responds to a medication called levodopa - Your doctor feels your Parkinson's symptoms are not well enough controlled by your current treatment -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03713957 — Alkahest, Inc.

NCT03713957 · Alkahest, Inc.
Completed Phase 2 Est. completion 20 July 2020
🇦🇺 AU 🇫🇷 FR 🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Parkinson's Disease and have had symptoms for at least 1 year. - You have been diagnosed with Parkinson's Disease along with mild memory or thinking problems, or Parkinson...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05508867 — Merck Sharp & Dohme LLC

NCT05508867 · Merck Sharp & Dohme LLC
Completed Phase 2 Est. completion 3 September 2025
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with classical Hodgkin lymphoma (a specific type of blood cancer), confirmed by a tissue biopsy, that shows up on a specific type of PET scan (FDG-PET). - Your lymphoma has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04662710 — Merck Sharp & Dohme LLC

NCT04662710 · Merck Sharp & Dohme LLC
Completed Phase 3 Est. completion 29 October 2024
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇨🇱 CL

**Who might be able to join this trial:** - You have been diagnosed with stomach or esophageal cancer (specifically adenocarcinoma) that has spread or cannot be surgically removed, and you have not yet received any treatment for it - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01602549 — GlaxoSmithKline

NCT01602549 · GlaxoSmithKline
Completed Phase 2 Est. completion 1 May 2014
🇦🇺 AU 🇩🇪 DE 🇸🇪 SE 🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with Parkinson's disease at a moderate stage (not too early, not the most severe stage), and your movement symptoms are not fully controlled by your current Parkinson's me...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06036836 — Merck Sharp & Dohme LLC

NCT06036836 · Merck Sharp & Dohme LLC
Completed Phase 2 Est. completion 12 March 2026
🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

**Who might be able to join this trial:** **For Cohort A (skin cancer group) only:** - You have been confirmed through a tissue test to have skin squamous cell carcinoma (a type of skin cancer) that can be removed by surgery, and the cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03783078 — Merck Sharp & Dohme LLC

NCT03783078 · Merck Sharp & Dohme LLC
Completed Phase 3 Est. completion 15 February 2022
🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇮🇹 IT 🇳🇿 NZ

**Who might be able to join this trial:** - You are male or female and at least 12 years old at the time of signing the consent form. - You have been diagnosed with Merkel cell carcinoma (a type of skin cancer) that has come back in the sa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03358472 — Incyte Corporation

NCT03358472 · Incyte Corporation
Completed Phase 3 Est. completion 19 July 2018
🇦🇺 AU 🇦🇹 AT 🇨🇦 CA 🇭🇺 HU 🇮🇹 IT

**Who might be able to join this trial:** - Your cancer must be measurable using standard imaging scans (based on specific medical guidelines called RECIST v1.1). - You must be fairly active and able to carry out normal daily activities wit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04071847 — Abbott Medical Devices

NCT04071847 · Abbott Medical Devices
Recruiting Not Applicable Est. completion 1 September 2029
🇦🇺 AU 🇫🇮 FI 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

**Who might be able to join this trial:** - You are scheduled to have a new brain stimulation device implanted, or have an existing device's battery replaced, using an Abbott deep brain stimulation system, within the next 180 days. - You (o...

🇦🇺 AU site

Trial: NCT06732180 — Gain Therapeutics, Inc.

NCT06732180 · Gain Therapeutics, Inc.
Recruiting Phase 1 Est. completion 30 November 2025
🇦🇺 AU

**Who might be able to join this trial:** - You are willing and able to give written consent and follow the study's rules and requirements - You are between 30 and 85 years old (any sex) - You have been diagnosed with Parkinson's disease (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04152863 — Merck Sharp & Dohme LLC

NCT04152863 · Merck Sharp & Dohme LLC
Terminated Phase 2 Est. completion 12 July 2023
🇦🇺 AU 🇨🇱 CL 🇫🇷 FR 🇩🇪 DE 🇮🇱 IL

**Who might be able to join this trial:** - You have been diagnosed with advanced or metastatic melanoma (skin cancer that has spread), confirmed by a lab test. - Your melanoma is classified as Stage III or Stage IV. - You have never been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04935762 — CuraSen Therapeutics, Inc.

NCT04935762 · CuraSen Therapeutics, Inc.
Withdrawn Phase 2 Est. completion 1 December 2024
🇦🇺 AU

**Who might be able to join this trial:** - You are between 30 and 80 years old (inclusive) at the time you give your consent to take part. - You have been diagnosed with Parkinson's Disease using a specific standard set of diagnostic guid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07066137 — IRCCS Centro Neurolesi Bonino Pulejo

NCT07066137 · IRCCS Centro Neurolesi Bonino Pulejo
Active, Not Recruiting Not Applicable Est. completion 5 May 2026
🇮🇹 IT

Who might be able to join this trial: - You have scored 20 or higher on a standard memory and thinking test called the Montreal Cognitive Assessment (MoCA), taking into account your age and education level. Who may not be able to join: - Y...

Trial: NCT04070495 — Kyowa Kirin Co., Ltd.

NCT04070495 · Kyowa Kirin Co., Ltd.
Completed Phase 1 Est. completion 19 November 2019
🇯🇵 JP

Who might be able to join this trial: - You are willing to give written consent to take part in this study voluntarily - You are a Japanese man aged between 20 and 44 years old at the time of signing the consent form - Your Body Mass Index...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)